CareDx (CDNA) Stock Price, News & Analysis

Company Overview

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $24.38 to $25.69
• 50-Day Range: $21.17 to $32.20
• 52-Week Range: $7.42 to $34.84
• Volume: 548,186 shs
• Average Volume: 795,245 shs
• Market Capitalization: $1.34 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.60
• Consensus Rating: Hold

CareDx Stock Analysis - MarketRank™

CareDx scored higher than 75% of companies evaluated by MarketBeat, and ranked 346th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

CareDx has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

CareDx has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CareDx are expected to grow in the coming year, from ($0.70) to ($0.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CareDx is -9.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CareDx is -9.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CareDx has a P/B Ratio of 5.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.12% of the float of CareDx has been sold short.

Short Interest Ratio / Days to Cover

CareDx has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CareDx has recently decreased by 11.01%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CareDx does not currently pay a dividend.

Dividend Growth

CareDx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.66

Percentage of Shares Shorted

6.12% of the float of CareDx has been sold short.

Short Interest Ratio / Days to Cover

CareDx has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CareDx has recently decreased by 11.01%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.03

News Sentiment

CareDx has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for CareDx this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for CDNA on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added CareDx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $125,000.00 in company stock.

Percentage Held by Insiders

Only 4.90% of the stock of CareDx is held by insiders.

CDNA Stock Analysis - Frequently Asked Questions

How have CDNA shares performed this year?

CareDx's stock was trading at $12.00 on January 1st, 2024. Since then, CDNA shares have increased by 108.0% and is now trading at $24.96.
View the best growth stocks for 2024 here.

How were CareDx's earnings last quarter?

CareDx, Inc (NASDAQ:CDNA) announced its earnings results on Monday, November, 4th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.11. The firm's revenue for the quarter was up 23.4% compared to the same quarter last year.

Who are CareDx's major shareholders?

CareDx's top institutional shareholders include Bellevue Group AG (5.87%), ARK Investment Management LLC (5.74%), State Street Corp (3.80%) and Sumitomo Mitsui Trust Group Inc. (3.14%). Insiders that own company stock include Reginald Seeto, Peter Maag, Alexander L Johnson, Michael Goldberg, Grace Colon and George Bickerstaff.
View institutional ownership trends.

How do I buy shares of CareDx?

Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CareDx investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/04/2024
• Today: 12/03/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/26/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:CDNA
• CUSIP: N/A
• CIK: 1217234
• Web: www.caredxinc.com
• Phone: (415) 287-2300
• Fax: 415-287-2450
• Employees: 740
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $29.60
• High Stock Price Target: $35.00
• Low Stock Price Target: $18.00
• Potential Upside/Downside: +18.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-190,280,000.00
• Net Margins: -45.90%
• Pretax Margin: -45.80%
• Return on Equity: -53.70%
• Return on Assets: -30.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.10
• Quick Ratio: 3.87

Sales & Book Value

• Annual Sales: $280.32 million
• Price / Sales: 4.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.83 per share
• Price / Book: 5.17

Miscellaneous

• Outstanding Shares: 53,630,000
• Free Float: 51,006,000
• Market Cap: $1.34 billion
• Optionable: Optionable
• Beta: 1.84